# Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma

> **NCT03352947** · PHASE2 · COMPLETED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 79 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03352947
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-03
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-11-27
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352947, "Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03352947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*